FDA approves first drug for hallucinations in Parkinson's disease

The FDA has approved a new drug called Nuplazid (pimavanserin) for treating hallucinations and delusions caused by Parkinson's disease psychosis. This is the first medication ever approved specifically for this condition, which affects many people with Parkinson's disease. In a 6-week study of 199 patients, those taking Nuplazid had fewer and less severe hallucinations and delusions compared to those on a placebo. Importantly, the drug did not worsen movement problems, which is a common concern with other antipsychotic medicines. The recommended dose is one 34 mg tablet daily, with no need to slowly increase the dose. However, dose adjustments may be needed if you take certain other medications. This approval gives patients and doctors a new treatment option for a challenging symptom. If you or a loved one has Parkinson's disease and experiences hallucinations or delusions, talk to your doctor about whether Nuplazid might be appropriate. As with any new medicine, it is important to discuss potential benefits and risks with your healthcare provider.